W. Jeffrey Allard, Ph.D

Jeff earned his Ph.D from Dartmouth College, in Biochemistry. Since obtaining his Doctorate, Dr. Allard has brought six "new to the world" diagnostic tests through FDA, with 30+ FDA clearances and approvals. He has launched sixteen new products. He has authored over 100 scientific papers and abstracts.

Prior to moving to the consulting world, Jeff served as Director of Development for Caris Life Sciences, where he designed and implemented a Product Development System, designed multiple clinical and regulatory strategies for novel multiplex oncology tests, wrote clinical protocols for prospective research and Premarket Approval (PMA)-submission trials, and designed a patient registry. He also served as Vice President and Chief Scientific Officer of Fujirebio Diagnostics, Inc. (FDI). He directed the Applied Research, Product Development, Clinical Affairs, Regulatory Affairs, and Process Engineering departments.

Prior to joining FDI in 2004, Dr. Allard previously held positions as Vice President of Clinical Research and Development for Immunicon Corporation (Currently Veridex LLC, a division of Johnson & Johnson) where he designed and managed clinical trials that led to the worldwide introduction of the CellSearch Assay for measurement of circulating tumor cells (CTC). Dr. Allard designed three clinical trials that led to FDA clearance of CTC for prediction of overall survival and progression free survival in patients with breast, colorectal, and prostate cancers. Dr. Allard is an inventor on 12 patents for novel technologies, including new tests for gynecologic cancers, circulating tumor cells, complexed PSA for early detection of prostate cancer, and other diagnostic technologies.